Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Pedersen, Niels C; Kim, Yunjeong; Liu, Hongwei; Galasiti Kankanamalage, Anushka C; Eckstrand, Chrissy; Groutas, William C; Bannasch, Michael; Meadows, Juliana M; Chang, Kyeong-Ok

Seven of the 20 cats in the GC376 treatment trial, all of which received at least 12 weeks of continuous treatment, were categorized as potential treatment successes based on more than 12 weeks of disease remission following cessation of treatment ( Figure 2 ). Six of these kittens presented with acute effusive disease of the abdomen (CT15, CT17, CT18, CT21, CT23) or chest (CT20) at 3.3-4.4 months of age and were treated continuously for 12 or 17 (cat CT21) weeks (Table 1, Figure 2) . A seventh cat (CT04), a 6.8-year-old random-bred castrated male presenting with dry FIP limited to a mesenteric lymph node, also achieved Section from the greatly thickened wall of resected colon from cat CT03. Immunoperoxidase (brown color) staining for feline infectious peritonitis virus antigen is seen in macrophages around the periphery of a granulomatous lesion. Virus persistence in the colon occurred in the presence of treatment and regression of other signs of disease (eg, effusive peritonitis) a long-term remission, but only after four rounds of treatment of increasing duration (Table 1, Figure 2 ).